CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Royalty income	$ 719	$ 728	$ 3,052	$ 4,181
Collaboration revenue	145	136	1,512	521
Research grants	0	243	275	417
Other revenues	3	10	55	44
Total revenues	867	1,117	4,894	5,163
Expenses:
Research and development	7,913	7,551	26,702	26,417
License fees - research and development	91	510	314	660
Royalty expense	73	73	308	420
General and administrative	3,123	4,007	10,853	11,753
Depreciation and amortization	179	291	774	1,063
Total expenses	11,379	12,432	38,951	40,313
Operating loss	(10,512)	(11,315)	(34,057)	(35,150)
Other income:
Interest income	12	14	36	43
Total other income	12	14	36	43
Net loss	$ (10,500)	$ (11,301)	$ (34,021)	$ (35,107)
Net loss per share - basic and diluted	$ (0.17)	$ (0.33)	$ (0.63)	$ (1.04)
Weighted-average shares - basic and diluted	60,599	33,848	54,104	33,803